Alirocumab
- Generic Name
- Alirocumab
- Brand Names
- Praluent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1245916-14-6
- Unique Ingredient Identifier
- PP0SHH6V16
- Background
Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutic...
- Indication
Alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor activity that is indicated for:
(i) use in reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease , and/or
...
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolaemia (HoFH), Myocardial Infarction, Stroke, Unstable Angina Pectoris, Primary Hyperlipidemia
- Associated Therapies
- -
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Institute for Clinical and Experimental Medicine
- Target Recruit Count
- 126
- Registration Number
- NCT04193306
- Locations
- 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Czechia
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Imperial College London
- Registration Number
- NCT03750760
- Locations
- 🇬🇧
Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
🇬🇧Hull Royal Infirmary, Hull, North Humberside, United Kingdom
🇬🇧Northwick Park Hospital, Harrow, Middlesex, United Kingdom
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 97
- Registration Number
- NCT03718286
- Locations
- 🇨🇦
Hamilton Health Sciences, General Hospital, Hamilton, Ontario, Canada
The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Kobe University
- Target Recruit Count
- 24
- Registration Number
- NCT03552432
- Locations
- 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan
PCSK9 Inhibition After Heart Transplantation
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 120
- Registration Number
- NCT03537742
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Kobe University
- Target Recruit Count
- 31
- Registration Number
- NCT03533959
- Locations
- 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 20
- Registration Number
- NCT03507374
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03344692
- Locations
- 🇫🇷
University Hospital of Nantes, Nantes, France
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
- Conditions
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 140
- Registration Number
- NCT03207945
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03156621
- Locations
- 🇨🇳
Regeneron Study Site, Taipei, Taiwan
🇺🇦Regeneron Research Site, Kyiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.